Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective J
Arrowhead Pharmaceuticals, Inc. jumped on Phase 3 plozasiran sHTG data; see key catalysts, risks, and upside vs Ionis ahead of filings. Click for this ARWR update.
View interactive chart, options flow, and AI analysis for SRPT on Zorveq Finance.
Open SRPT Chart & Analysis →